Cannabinoid receptor#CB1

The existence of cannabinoid receptors in the brain was discovered from in vitro studies in the 1980s, with the receptor designated as the cannabinoid receptor type 1 or CB1.{{cite journal | vauthors = Elphick MR, Egertová M | title = The neurobiology and evolution of cannabinoid signalling | journal = Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences | volume = 356 | issue = 1407 | pages = 381–408 | date = March 2001 | pmid = 11316486 | pmc = 1088434 | doi = 10.1098/rstb.2000.0787 | type = Review }}{{cite journal | vauthors = Pertwee RG | title = Cannabinoid pharmacology: the first 66 years | journal = British Journal of Pharmacology | volume = 147 | issue = Suppl 1 | pages = S163–71 | date = January 2006 | pmid = 16402100 | pmc = 1760722 | doi = 10.1038/sj.bjp.0706406 | type = Review }} The DNA sequence that encodes a G-protein-coupled cannabinoid receptor in the human brain was identified and cloned in 1990.{{cite journal | vauthors = Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI | title = Structure of a cannabinoid receptor and functional expression of the cloned cDNA | journal = Nature | volume = 346 | issue = 6284 | pages = 561–4 | date = August 1990 | pmid = 2165569 | doi = 10.1038/346561a0 | bibcode = 1990Natur.346..561M | s2cid = 4356509 }}{{cite journal | vauthors = Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG | display-authors = 6 | title = International Union of Pharmacology. XXVII. Classification of cannabinoid receptors | journal = Pharmacological Reviews | volume = 54 | issue = 2 | pages = 161–202 | date = June 2002 | pmid = 12037135 | doi = 10.1124/pr.54.2.161| s2cid = 8259002 | type = Review }} These discoveries led to determination in 1993 of a second brain cannabinoid receptor named cannabinoid receptor type 2 or CB2.

A neurotransmitter for a possible endocannabinoid system in the brain and peripheral nervous system, anandamide (from 'ananda', Sanskrit for 'bliss'), was first characterized in 1992,{{cite book |vauthors=Mechoulam R, Fride E |editor=Pertwee RG |title=Cannabinoid receptors |publisher=Academic Press |location=Boston |year=1995 |pages=233–258 |chapter=The unpaved road to the endogenous brain cannabinoid ligands, the anandamides |isbn=978-0-12-551460-6 | type = Review}}{{cite journal | vauthors = Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R | display-authors = 6 | title = Isolation and structure of a brain constituent that binds to the cannabinoid receptor | journal = Science | volume = 258 | issue = 5090 | pages = 1946–9 | date = December 1992 | pmid = 1470919 | doi = 10.1126/science.1470919 | bibcode = 1992Sci...258.1946D }}{{cite journal | vauthors = Hanus LO | title = Discovery and isolation of anandamide and other endocannabinoids | journal = Chemistry & Biodiversity | volume = 4 | issue = 8 | pages = 1828–41 | date = August 2007 | pmid = 17712821 | doi = 10.1002/cbdv.200790154 | s2cid = 745528 }} followed by discovery of other fatty acid neurotransmitters that behave as endogenous cannabinoids having a low-to-high range of efficacy for stimulating CB1 receptors in the brain and CB2 receptors in the periphery.

{{Main|Cannabinoid receptor type 1}}

Cannabinoid receptor type 1 (CB₁) receptors are thought to be one of the most widely expressed G_αi protein-coupled receptors in the brain. One mechanism through which they function is endocannabinoid-mediated depolarization-induced suppression of inhibition, a very common form of retrograde signaling, in which the depolarization of a single neuron induces a reduction in GABA-mediated neurotransmission. Endocannabinoids released from the depolarized post-synaptic neuron bind to CB₁ receptors in the pre-synaptic neuron and cause a reduction in GABA release due to limited presynaptic calcium ions entry.{{medcn|date=December 2017}}

They are also found in other parts of the body. For instance, in the liver, activation of the CB₁ receptor is known to increase de novo lipogenesis.

{{Main|Cannabinoid receptor type 2}}

CB₂ receptors are expressed on T cells of the immune system, on macrophages and B cells, in hematopoietic cells, and in the brain and CNS (2019).{{cite book |vauthors=Onaivi J |chapter=Endocannabinoid System Components: Overview and Tissue Distribution |chapter-url=https://doi.org/10.1007/978-3-030-21737-2_1 |title=Recent Advances in Cannabinoid Physiology and Pathology |veditors=Bukiya A |publisher=Springer |location=Cham. |series=Advances in Experimental Medicine and Biology |year=2019 |volume=1162 |pages=1–12 |doi=10.1007/978-3-030-21737-2_1 |pmid=31332731 |isbn=978-3-030-21736-5 |s2cid=198172390 |access-date=19 October 2021 |archive-date=20 April 2023 |archive-url=https://web.archive.org/web/20230420210524/https://link.springer.com/chapter/10.1007/978-3-030-21737-2_1 |url-status=live }} They also have a function in keratinocytes. They are also expressed on peripheral nerve terminals. These receptors play a role in antinociception, or the relief of pain. In the brain, they are mainly expressed by microglial cells, where their role remains unclear. While the most likely cellular targets and executors of the CB₂ receptor-mediated effects of endocannabinoids or synthetic agonists are the immune and immune-derived cells (e.g. leukocytes, various populations of T and B lymphocytes, monocytes/macrophages, dendritic cells, mast cells, microglia in the brain, Kupffer cells in the liver, astrocytes, etc.), the number of other potential cellular targets is expanding, now including endothelial and smooth muscle cells, fibroblasts of various origins, cardiomyocytes, and certain neuronal elements of the peripheral or central nervous systems (2011).

The existence of additional cannabinoid receptors has long been suspected, due to the actions of compounds such as abnormal cannabidiol that produce cannabinoid-like effects on blood pressure and inflammation, yet do not activate either CB₁ or CB₂. Recent research strongly supports the hypothesis that the N-arachidonoyl glycine (NAGly) receptor GPR18 is the molecular identity of the abnormal cannabidiol receptor and additionally suggests that NAGly, the endogenous lipid metabolite of anandamide (also known as arachidonoylethanolamide or AEA), initiates directed microglial migration in the CNS through activation of GPR18. Other molecular biology studies have suggested that the orphan receptor GPR55 should in fact be characterised as a cannabinoid receptor, on the basis of sequence homology at the binding site. Subsequent studies showed that GPR55 does indeed respond to cannabinoid ligands. This profile as a distinct non-CB₁/CB₂ receptor that responds to a variety of both endogenous and exogenous cannabinoid ligands, has led some groups to suggest GPR55 should be categorized as the CB₃ receptor, and this re-classification may follow in time. However this is complicated by the fact that another possible cannabinoid receptor has been discovered in the hippocampus, although its gene has not yet been cloned, suggesting that there may be at least two more cannabinoid receptors to be discovered, in addition to the two that are already known. GPR119 has been suggested as a fifth possible cannabinoid receptor, while the PPAR family of nuclear hormone receptors can also respond to certain types of cannabinoid.{{cite journal | vauthors = O'Sullivan SE | title = An update on PPAR activation by cannabinoids | journal = British Journal of Pharmacology | volume = 173 | issue = 12 | pages = 1899–910 | date = June 2016 | pmid = 27077495 | pmc = 4882496 | doi = 10.1111/bph.13497 }}

Cannabinoid receptors are activated by cannabinoids, generated naturally inside the body (endocannabinoids) or introduced into the body as cannabis or a related synthetic compound. Similar responses are produced when introduced in alternative methods, only in a more concentrated form than what is naturally occurring.

After the receptor is engaged, multiple intracellular signal transduction pathways are activated. At first, it was thought that cannabinoid receptors mainly inhibited the enzyme adenylate cyclase (and thereby the production of the second messenger molecule cyclic AMP), and positively influenced inwardly rectifying potassium channels (=Kir or IRK). However, a much more complex picture has appeared in different cell types, implicating other potassium ion channels, calcium channels, protein kinase A and C, Raf-1, ERK, JNK, p38, c-fos, c-jun and many more. For example, in human primary leukocytes CB₂ displays a complex signalling profile, activating adenylate cyclase via stimulatory G_αs alongside the classical G_αi signalling, and induces ERK, p38 and pCREB pathways.{{cite journal| vauthors = Saroz Y, Kho DT, Glass M, Graham ES, Grimsey NL | date = October 2019 |title = Cannabinoid Receptor 2 (CB2) Signals via G-alpha-s and Induces IL-6 and IL-10 Cytokine Secretion in Human Primary Leukocytes |journal=ACS Pharmacology & Translational Science | pages = 414–428 | doi = 10.1021/acsptsci.9b00049 | doi-access = free | pmid = 32259074 | pmc = 7088898 | volume = 2 | issue = 6 }}

Separation between the therapeutically undesirable psychotropic effects, and the clinically desirable ones, however, has not been reported with agonists that bind to cannabinoid receptors. THC, as well as the two major endogenous compounds identified so far that bind to the cannabinoid receptors —anandamide and 2-arachidonylglycerol (2-AG)— produce most of their effects by binding to both the CB₁ and CB₂ cannabinoid receptors. While the effects mediated by CB₁, mostly in the central nervous system, have been thoroughly investigated, those mediated by CB₂ are not equally well defined.

Prenatal cannabis exposure (PCE) has been shown to perturb the fetal endogenous cannabinoid signaling system. This perturbation has not been shown to directly affect neurodevelopment nor cause lifelong cognitive, behavioral, or functional abnormalities, but it may predispose offspring to abnormalities in cognition and altered emotionality from post-natal factors.{{cite journal | vauthors = Richardson KA, Hester AK, McLemore GL | title = Prenatal cannabis exposure - The "first hit" to the endocannabinoid system | journal = Neurotoxicology and Teratology | volume = 58 | pages = 5–14 | date = 2016 | pmid = 27567698 | doi = 10.1016/j.ntt.2016.08.003 | s2cid = 5656802 | department = review }} Additionally, PCE may alter the wiring of brain circuitry in foetal development and cause significant molecular modifications to neurodevelopmental programs that may lead to neurophysiological disorders and behavioural abnormalities.{{cite journal | vauthors = Calvigioni D, Hurd YL, Harkany T, Keimpema E | title = Neuronal substrates and functional consequences of prenatal cannabis exposure | journal = European Child & Adolescent Psychiatry | volume = 23 | issue = 10 | pages = 931–41 | date = October 2014 | pmid = 24793873 | pmc = 4459494 | doi = 10.1007/s00787-014-0550-y | department = review }}

{{main|Medical cannabis}}

Synthetic tetrahydrocannabinol (THC) is prescribed under the INN dronabinol or the brand name Marinol, to treat vomiting and for enhancement of appetite, mainly in people with AIDS as well as for refractory nausea and vomiting in people undergoing chemotherapy.{{cite journal | vauthors = Badowski ME | title = A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics | journal = Cancer Chemotherapy and Pharmacology | volume = 80 | issue = 3 | pages = 441–449 | date = September 2017 | pmid = 28780725 | pmc = 5573753 | doi = 10.1007/s00280-017-3387-5 }} Use of synthetic THC is becoming more common as the known benefits become more prominent within the medical industry. THC is also an active ingredient in nabiximols, a specific extract of Cannabis that was approved as a botanical drug in the United Kingdom in 2010 as a mouth spray for people with multiple sclerosis to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms.{{cite web|title=Sativex Oromucosal Spray - Summary of Product Characteristics|url=http://www.medicines.org.uk/emc/medicine/23262|publisher=UK Electronic Medicines Compendium|language=en|date=March 2015|access-date=2017-10-09|archive-url=https://web.archive.org/web/20160822231728/http://www.medicines.org.uk/emc/medicine/23262|archive-date=2016-08-22|url-status=dead}}

{{further|Cannabinoid receptor type 1#Ligands|Cannabinoid receptor type 2#Ligands}}

Binding affinity and selectivity of cannabinoid ligands:

• Cannabinoid receptor antagonist
• Endocannabinoid enhancer
• Endocannabinoid reuptake inhibitor
• Cannabidiol
• Effects of cannabis

{{reflist|refs=

{{cite journal | vauthors = Howlett AC | title = The cannabinoid receptors | journal = Prostaglandins & Other Lipid Mediators | volume = 68–69 | pages = 619–31 | date = August 2002 | pmid = 12432948 | doi = 10.1016/S0090-6980(02)00060-6 }}

{{cite journal | vauthors = Mackie K | title = Cannabinoid receptors: where they are and what they do | journal = Journal of Neuroendocrinology | volume = 20 | issue = Suppl 1 | pages = 10–4 | date = May 2008 | pmid = 18426493 | doi = 10.1111/j.1365-2826.2008.01671.x | s2cid = 20161611 | doi-access = free }}

{{cite journal | vauthors = Graham ES, Ashton JC, Glass M | title = Cannabinoid Receptors: A brief history and what not | journal = Frontiers in Bioscience | volume = 14 | issue = 14 | pages = 944–57 | date = January 2009 | pmid = 19273110 | doi = 10.2741/3288 | doi-access = free }}

{{cite journal | vauthors = Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P | display-authors = 6 | title = Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations | journal = European Journal of Biochemistry | volume = 232 | issue = 1 | pages = 54–61 | date = August 1995 | pmid = 7556170 | doi = 10.1111/j.1432-1033.1995.tb20780.x | doi-access = free }}

{{cite journal | vauthors = Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI | title = Structure of a cannabinoid receptor and functional expression of the cloned cDNA | journal = Nature | volume = 346 | issue = 6284 | pages = 561–4 | date = August 1990 | pmid = 2165569 | doi = 10.1038/346561a0 | bibcode = 1990Natur.346..561M | s2cid = 4356509 }}

{{cite journal | vauthors = Gérard CM, Mollereau C, Vassart G, Parmentier M | title = Molecular cloning of a human cannabinoid receptor which is also expressed in testis | journal = The Biochemical Journal | volume = 279 | issue = Pt 1 | pages = 129–34 | date = October 1991 | pmid = 1718258 | pmc = 1151556 | doi = 10.1042/bj2790129 }}

{{cite journal | vauthors = Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ | display-authors = 6 | title = The orphan receptor GPR55 is a novel cannabinoid receptor | journal = British Journal of Pharmacology | volume = 152 | issue = 7 | pages = 1092–101 | date = December 2007 | pmid = 17876302 | pmc = 2095107 | doi = 10.1038/sj.bjp.0707460 }}

{{cite journal | vauthors = Munro S, Thomas KL, Abu-Shaar M | title = Molecular characterization of a peripheral receptor for cannabinoids | journal = Nature | volume = 365 | issue = 6441 | pages = 61–5 | date = September 1993 | pmid = 7689702 | doi = 10.1038/365061a0 | bibcode = 1993Natur.365...61M | s2cid = 4349125 }}

{{cite journal | vauthors = Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertáler L, Wang L, Kunos G | display-authors = 6 | title = Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity | journal = The Journal of Clinical Investigation | volume = 115 | issue = 5 | pages = 1298–305 | date = May 2005 | pmid = 15864349 | pmc = 1087161 | doi = 10.1172/JCI23057 }}

{{cite journal | vauthors = Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G | display-authors = 6 | title = Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 96 | issue = 24 | pages = 14136–41 | date = November 1999 | pmid = 10570211 | pmc = 24203 | doi = 10.1073/pnas.96.24.14136 | bibcode = 1999PNAS...9614136J | doi-access = free }}

{{cite journal | vauthors = McHugh D, Tanner C, Mechoulam R, Pertwee RG, Ross RA | title = Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2 | journal = Molecular Pharmacology | volume = 73 | issue = 2 | pages = 441–50 | date = February 2008 | pmid = 17965195 | doi = 10.1124/mol.107.041863 | s2cid = 15182303 }}

{{cite journal | vauthors = McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM, Bradshaw HB | title = N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor | journal = BMC Neuroscience | volume = 11 | pages = 44 | date = March 2010 | pmid = 20346144 | pmc = 2865488 | doi = 10.1186/1471-2202-11-44 | doi-access = free }}

{{cite journal | vauthors = Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, Riddick M, Dowell S, Staton PC, Green P, Shabon U, Bao W, Aiyar N, Yue TL, Brown AJ, Morrison AD, Douglas SA | display-authors = 6 | title = The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects | journal = British Journal of Pharmacology | volume = 152 | issue = 5 | pages = 825–31 | date = November 2007 | pmid = 17704827 | pmc = 2190033 | doi = 10.1038/sj.bjp.0707419 }}

{{cite journal | vauthors = Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet C | display-authors = 6 | title = Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents | journal = Cell Metabolism | volume = 3 | issue = 3 | pages = 167–75 | date = March 2006 | pmid = 16517404 | doi = 10.1016/j.cmet.2006.02.004 | doi-access = free }}

{{cite journal | vauthors = de Fonseca FR, Schneider M | title = The endogenous cannabinoid system and drug addiction: 20 years after the discovery of the CB1 receptor | journal = Addiction Biology | volume = 13 | issue = 2 | pages = 143–6 | date = June 2008 | pmid = 18482429 | doi = 10.1111/j.1369-1600.2008.00116.x | s2cid = 205400322 | url = http://www.zi-mannheim.de/fileadmin/user_upload/redakteure/psychopharma/De_Fonseca_2008.pdf | url-status = dead | archive-url = https://web.archive.org/web/20110718033850/http://www.zi-mannheim.de/fileadmin/user_upload/redakteure/psychopharma/De_Fonseca_2008.pdf | archive-date = 2011-07-18 }}

{{cite journal | vauthors = Brown AJ | title = Novel cannabinoid receptors | journal = British Journal of Pharmacology | volume = 152 | issue = 5 | pages = 567–75 | date = November 2007 | pmid = 17906678 | pmc = 2190013 | doi = 10.1038/sj.bjp.0707481 }}

{{cite journal | vauthors = Demuth DG, Molleman A | title = Cannabinoid signalling | journal = Life Sciences | volume = 78 | issue = 6 | pages = 549–63 | date = January 2006 | pmid = 16109430 | doi = 10.1016/j.lfs.2005.05.055 }}

}}

• {{MeshName|Cannabinoid+Receptors}}

{{G protein-coupled receptors}}

{{Cannabinoidergics}}

{{DEFAULTSORT:Cannabinoid Receptor}}

Category:G protein-coupled receptors